

12. Franceschini G, Sirtori CR, Capurso A Ilnd et al (1980) A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. *J Clin Invest* 66:892–900
13. Frikke-Schmidt R, Nordestgaard BG, Stene MC et al (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA* 299:2524–2532
14. Grunfeld C, Feingold KR (2008) HDL and innate immunity: a tale of two apolipoproteins. *J Lipid Res* 49:1605–1606
15. Ji A, Wroblewski JM, Cai L et al (2012) Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. *J Lipid Res* 53:446–455
16. Ji J, Watts GF, Johnson AG et al (2006) High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. *J Clin Endocrinol Metab* 91:973–979
17. Ji Y, Jian B, Wang N et al (1997) Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. *J Biol Chem* 272:20982–20985
18. Khera AV, Cuchel M, De La Llera-Moya M et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *N Engl J Med* 364:127–135
19. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. *Pharmacol Rev* 58:342–374
20. Martinez LO, Jacquet S, Esteve JP et al (2003) Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. *Nature* 421:75–79
21. Matsuura F, Wang N, Chen W et al (2006) HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. *J Clin Invest* 116:1435–1442
22. Navab M, Reddy ST, Van Lenten BJ et al (2009) The role of dysfunctional HDL in atherosclerosis. *J Lipid Res* 50(Suppl):S145–149
23. Niesor EJ, Magg C, Ogawa N et al (2010) Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. *J Lipid Res* 51:3443–3454
24. Nofer JR, Van Eck M (2011) HDL scavenger receptor class B type I and platelet function. *Curr Opin Lipidol* 22:277–282
25. Packard CJ, Demant T, Stewart JP et al (2000) Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. *J Lipid Res* 41:305–318
26. Parhofer KG, Barrett PH (2006) Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. *J Lipid Res* 47:1620–1630
27. Persegol L, Verges B, Foissac M et al (2006) Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. *Diabetologia* 49:1380–1386
28. Reiner Z, Catapano AL, De Backer G et al (2011) ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 32:1769–1818
29. Roselaar SE, Daugherty A (1998) Apolipoprotein E-deficient mice have impaired innate immune responses to listeria monocytogenes in vivo. *J Lipid Res* 39:1740–1743
30. Schmit, Barlage S (2006) High-density-Lipoproteine und Atherosklerose. In: Schwandt P, Parhofer K (Hrsg) *Handbuch der Fettstoffwechselstörungen*. Schattauer, Stuttgart, S 483–518
31. Sniderman AD, Williams K, Contois JH et al (2011) A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes* 4:337–345
32. Sorrentino SA, Besler C, Rohrer L et al (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. *Circulation* 121:110–122
33. Tall AR (2009) The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. *Am J Cardiol* 104:39E–45E
34. Terasaka N, Yu S, Yvan-Charvet L et al (2008) ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. *J Clin Invest* 118:3701–3713
35. Von Eckardstein A (2006) Störungen im Stoffwechsel der High-density-Lipoproteine. In: Schwandt P, Parhofer K (Hrsg) *Handbuch der Fettstoffwechselstörungen*. Schattauer, Stuttgart, S 112–146
36. Wang N, Lan D, Chen W et al (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci U S A* 101:9774–9779
37. Wang Y, Zhu X, Wu G et al (2008) Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. *J Lipid Res* 49:1640–1645
38. Zhang Y, Da Silva JR, Reilly M et al (2005) Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. *J Clin Invest* 115:2870–2874

Kardiologe 2012 · 6:336–336
DOI 10.1007/s12181-012-0443-6
© Springer-Verlag 2012

G. Breithardt^{1,2} · **L.-I. Krämer**³ · **S. Willems**⁴

¹ Münster

² Department Kardiologie und Angiologie, Universitätsklinikum Münster, Münster

³ Medizinische Klinik II, Krankenhaus Merheim, Kliniken der Stadt Köln gGmbH, Köln

⁴ Klinik fuer Kardiologie mit Schwerpunkt Elektrophysiologie, Universitaeres Herzzentrum Hamburg, Hamburg

Erratum zu: Curriculum Spezielle Rhythmologie

Kardiologe (2012) 6:219–225.
<http://dx.doi.org/10.1007/s12181-012-0424-9>

Im oben genannten Beitrag wurde Herrn Prof. Willems eine falsche Institutsbezeichnung zugeordnet. Korrekt ist die folgende Institutszugehörigkeit:

S. Willems

Klinik für Kardiologie mit Schwerpunkt Elektrophysiologie, Universitäres Herzzentrum Hamburg.

Ferner wurde auf der Seite 223 im Absatz „Stufe 3“ die Abkürzung SVT nicht korrekt aufgelöst. Richtig ist: SVT = Supraventrikuläre Tachykardie.

Die auf S. 225 aufgeführte Übergangsregelung endet am 31.05.2014.

Wir bitten um Beachtung.

Korrespondenzadresse

Prof. Dr. G. Breithardt
Von-Esmarch-Str. 117, 48149 Münster
g.breithardt@uni-muenster.de

Prof. Dr. S. Willems
Klinik fuer Kardiologie mit Schwerpunkt Elektrophysiologie, Universitaeres Herzzentrum Hamburg
Martinistr. 52, 20246 Hamburg
willems@uke.de